Home	Fast Track My Amedeo FAQ About	Flying Publisher
Fast Track	FPG #8: Alternative Treatments in Psychiatry FPG #7: Critical Care in Neurology	Free Medical Books

Ovarian Neoplasms

Free Subscription 26.12.2011 3 Ann Oncol 1 Curr Opin Obstet Gynecol 1 Histopathology 2 Int J Cancer 1 Int J Oncol 4 J Clin Oncol 1 J Natl Cancer Inst 2 Lancet Oncol 2 Obstet Gynecol

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

Ann Oncol

1. BRAGA S
   Why do our patients get chemotherapy until the end of life?
   Ann Oncol. 2011;22:2345-8.
   PubMed     Text format     Related articles   
   
   
   
2. NAPPA U , Lindqvist O, Rasmussen BH, Axelsson B, et al
   Palliative chemotherapy during the last month of life.
   Ann Oncol. 2011;22:2375-80.
   PubMed     Text format     Related articles    Abstract available
   
   
   
3. WEBERPALS JI , Tu D, Squire JA, Amin MS, et al
   Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative study.
   Ann Oncol. 2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   

   
   Curr Opin Obstet Gynecol

4. RODRIGUEZ AO
   Personalized ovarian cancer treatment.
   Curr Opin Obstet Gynecol. 2011.
   PubMed     Text format     Related articles   
   
   
   

   
   Histopathology

5. ZHAO F , Siu MK, Jiang L, Tam KF, et al
   Overexpression of dedicator of cytokinesis I (Dock180) in ovarian cancer correlated with aggressive phenotype and poor patient survival.
   Histopathology. 2011;59:1163-72.
   PubMed     Text format     Related articles    Abstract available
   
   
   

   
   Int J Cancer

6. JACOB F , Goldstein DR, Bovin NV, Pochechueva T, et al
   Serum anti-glycan antibody detection of non-mucinous ovarian cancers by using a printed glycan array.
   Int J Cancer. 2011 Feb 23. doi: 10.1002/ijc.26002.
   PubMed     Text format     Related articles    Abstract available
   
   
   
7. MAEDA O , Shibata K, Hosono S, Fujiwara S, et al
   Spectrin alphaII and betaII tetramers contribute to platinum anticancer drug resistance in ovarian serous adenocarcinoma.
   Int J Cancer. 2011 Feb 15. doi: 10.1002/ijc.25983.
   PubMed     Text format     Related articles    Abstract available
   
   
   

   
   Int J Oncol

8. WANG D , Saga Y, Mizukami H, Sato N, et al
   Indoleamine-2,3-dioxygenase, an immunosuppressive enzyme that inhibits natural killer cell function, as a useful target for ovarian cancer therapy.
   Int J Oncol. 2011 Dec 13. doi: 10.3892/ijo.2011.1295.
   PubMed     Text format     Related articles    Abstract available
   
   
   

   
   J Clin Oncol

9. SOOD AK , Coleman RL, Ellis LM
   Moving Beyond Anti-Vascular Endothelial Growth Factor Therapy in Ovarian Cancer.
   J Clin Oncol. 2011.
   PubMed     Text format     Related articles   
   
   
   
10. KARLAN BY , Oza AM, Richardson GE, Provencher DM, et al
    Randomized, Double-Blind, Placebo-Controlled Phase II Study of AMG 386 Combined With Weekly Paclitaxel in Patients With Recurrent Ovarian Cancer.
    J Clin Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
11. HALBERT CH , Stopfer JE, McDonald J, Weathers B, et al
    Long-term reactions to genetic testing for BRCA1 and BRCA2 mutations: does time heal women's concerns?
    J Clin Oncol. 2011;29:4302-6.
    PubMed     Text format     Related articles    Abstract available
    
    
    
12. CHI DS , Bristow RE, Armstrong DK, Karlan BY, et al
    Is the easier way ever the better way?
    J Clin Oncol. 2011;29:4073-5.
    PubMed     Text format     Related articles   
    
    
    

    
    J Natl Cancer Inst

13. NICK AM , Stone RL, Armaiz-Pena G, Ozpolat B, et al
    Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death.
    J Natl Cancer Inst. 2011;103:1596-612.
    PubMed     Text format     Related articles    Abstract available
    
    
    

    
    Lancet Oncol

14. GOTLIEB WH , Amant F, Advani S, Goswami C, et al
    Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study.
    Lancet Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
15. COLEMAN RL , Duska LR, Ramirez PT, Heymach JV, et al
    Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer.
    Lancet Oncol. 2011;12:1109-17.
    PubMed     Text format     Related articles    Abstract available
    
    
    

    
    Obstet Gynecol

16. CHASE DM , Fedewa S, Chou TS, Chen A, et al
    Disparities in the allocation of treatment in advanced ovarian cancer: are there certain patient characteristics associated with nonstandard therapy?
    Obstet Gynecol. 2012;119:68-77.
    PubMed     Text format     Related articles    Abstract available
    
    
    
17. ROMERO IL , McCormick A, McEwen KA, Park S, et al
    Relationship of Type II Diabetes and Metformin Use to Ovarian Cancer Progression, Survival, and Chemosensitivity.
    Obstet Gynecol. 2012;119:61-7.
    PubMed     Text format     Related articles    Abstract available
    
    
    

Thank you for your interest in scientific medicine.

Amedeo is a Flying Publisher website.    Design: